Insights into the future of AML therapy: the increasing use of targeted agents

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, shares his perspectives on the future of acute myeloid leukemia (AML) therapy. Dr Levis discusses the declining utilization of cytotoxic therapy due to the emergence of targeted agents and highlights the potential of menin inhibitors. Moreover, Dr Levis addresses the existing gaps in care, particularly for patients with spliceosome mutations exhibiting myelodysplastic syndrome (MDS) characteristics. Finally, Dr Levis sheds light on the changing role of allogeneic transplantation in the management of AML. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.